For today’s show, I invited on Eden Rahim, Portfolio Manager for the Next Edge Biotech and Life Sciences Opportunities Fund. It’s been a bloodbath for biotech in the last two years – according to the S&P Biotechnology Select Industry Index, the sector has been down ~45-50%. At the same time, in 2023, also according to the S&P Biotechnology Select Industry Index, the sector is up about 4-5% already on the year (as of January 20, 2023). Whether this is a sign that things are looking up for biotech is still too early to tell, but I felt its worth discussing why its been hard times in biotech in 2021 and 2022. Eden and I also discuss what he’s looking for amongst the biotech rubble, in particular, why it’s so important to pay attention to how Phase 2b clinical trials are constructed. We close out with his biotech predications for 2023.

For more information about Eden Rahim and Next Edge Capital, please visit: https://www.nextedgecapital.com/funds/next-edge-biotech-and-life-sciences-opportunities-fund/overview/

You can Follow Eden Rahim on Twitter @EdenRahim: https://twitter.com/EdenRahim

Any information provided by the SNN Network YouTube channel is for general information only and must never be considered a substitute for professional advice. SNN Network makes no warranties or representations of any kind concerning the accuracy or suitability of the information contained on our channel. SNN Network may at any time and in our sole and absolute discretion remove, change or replace the information available on our channel, including comments. SNN Network is not liable for any direct, incidental, consequential, indirect or punitive damages arising out of access to or use of any content available on our channel, regardless of the accuracy or completeness of any such content. SNN Network disclaims any control over, relationship with, or endorsement of views expressed by other YouTube users. Any links to other websites are provided as a convenience and SNN Network encourages you to read the privacy statements and terms of use of our site and any third-party websites.